Rep. Greg Landsman Sells Bristol-Myers Squibb (NYSE:BMY) Stock

Representative Greg Landsman (D-Ohio) recently sold shares of Bristol-Myers Squibb NYSE: BMY. In a filing disclosed on April 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bristol-Myers Squibb stock on March 27th. The trade occurred in the Representative's "ROCKEFELLER CAPITAL MANAGEMENT (2)" account.

Representative Greg Landsman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of CrowdStrike NASDAQ: CRWD on 3/27/2025.
• Sold $1,001 - $15,000 in shares of Cadence Design Systems NASDAQ: CDNS on 3/27/2025.
• Sold $15,001 - $50,000 in shares of Simon Property Group NYSE: SPG on 3/27/2025.
• Sold $1,001 - $15,000 in shares of L3Harris Technologies NYSE: LHX on 3/27/2025.
• Sold $15,001 - $50,000 in shares of Visa NYSE: V on 3/27/2025.
• Sold $15,001 - $50,000 in shares of Cencora NYSE: COR on 3/27/2025.
• Sold $15,001 - $50,000 in shares of Alphabet NASDAQ: GOOGL on 3/27/2025.
• Sold $1,001 - $15,000 in shares of Ameriprise Financial NYSE: AMP on 3/27/2025.
• Sold $15,001 - $50,000 in shares of Salesforce NYSE: CRM on 3/27/2025.
• Sold $1,001 - $15,000 in shares of Equinix NASDAQ: EQIX on 3/27/2025.

Bristol-Myers Squibb Stock Down 2.7 %

BMY traded down $1.36 during trading hours on Tuesday, hitting $49.98. 15,675,831 shares of the company's stock were exchanged, compared to its average volume of 12,947,364. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The firm has a market cap of $101.70 billion, a P/E ratio of -11.31, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The firm has a 50 day moving average of $57.39 and a 200 day moving average of $56.73.

Remove Ads

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.96%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 1,823 shares of the business's stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.07% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BMY shares. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. UBS Group dropped their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday. Citigroup lifted their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Finally, Jefferies Financial Group raised Bristol-Myers Squibb from a "hold" rating to a "buy" rating and lifted their price target for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $57.67.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BMY. Wealthspire Advisors LLC grew its position in shares of Bristol-Myers Squibb by 0.6% during the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after acquiring an additional 170 shares during the last quarter. Edmp Inc. grew its position in Bristol-Myers Squibb by 0.4% during the 4th quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company's stock worth $2,353,000 after purchasing an additional 171 shares during the last quarter. Trust Point Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.9% during the fourth quarter. Trust Point Inc. now owns 9,423 shares of the biopharmaceutical company's stock worth $533,000 after buying an additional 172 shares during the period. Bedel Financial Consulting Inc. raised its stake in Bristol-Myers Squibb by 3.2% during the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock valued at $340,000 after acquiring an additional 175 shares during the last quarter. Finally, Horst & Graben Wealth Management LLC lifted its position in Bristol-Myers Squibb by 2.4% during the 4th quarter. Horst & Graben Wealth Management LLC now owns 7,538 shares of the biopharmaceutical company's stock worth $426,000 after acquiring an additional 179 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

About Representative Landsman

Greg Landsman (Democratic Party) is a member of the U.S. House, representing Ohio's 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Landsman (Democratic Party) is running for re-election to the U.S. House to represent Ohio's 1st Congressional District. He declared candidacy for the 2026 election. Greg Landsman was born in Cincinnati, Ohio, and lives in Mt. Washington, Ohio. Landsman earned a B.A. in economics and political science from Ohio University and an M.A. in theological studies, religion, and public policy from Harvard University in 2004. His career experience includes working as the executive director of The Strive Partnership with the KnowledgeWorks Foundation and the director of the Ohio Governor's Office of Faith-Based and Community Initiatives.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.